Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma

Yao Chen, Yusen Zhou, Suimin Qiu, Kaijuan Wang, Siwei Liu, Xuan Xian Peng, Junfeng Li, Eng M. Tan, Jian Ying Zhang

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The identification and characterization of tumor-associated antigens (TAAs) and their use in antigen mini-arrays for cancer immunodiagnosis has been of interest recently as an approach to cancer detection. In this study, autoantibodies in sera from a patient with HCC were used as probes to immunoscreen a HepG2 cDNA expression library for the identification of TAAs involved in malignant liver transformation. Recombinant proteins from two genes identified in this manner, Sui1 and RalA were expressed, purified and used as antigens in immunoassays to detect the presence of antibodies in sera from 77 patients with HCC, 30 with chronic hepatitis (CH), 30 with liver cirrhosis (LC) and 82 normal human sera (NHS). The prevalence of antibody to Sui1 and RalA in HCC were 11.7% (9/77) and 19.5% (15/77), respectively, which were significantly higher than prevalence in liver cirrhosis (3.3% and 3.3%), chronic hepatitis (0% and 0%) and normal human sera (0% and 0%). When Sui1 and RalA were added to a panel of eight other TAAs used in a previous study, the final cumulative prevalence of anti-TAA antibodies in HCC to the 10 TAA array was raised to 66.2% (51/77). The specificity for HCC compared with LC, CH and NHS, was 66.7%, 80.0%, and 87.8%, respectively. When anti-TAA was added to abnormal serum AFP as combined diagnostic markers, it raised the diagnostic sensitivity from 66.2% to 88.7%. AFP and anti-TAA were independent markers and the simultaneous use of these two markers significantly resulted in the increased sensitivity of HCC detection.

Original languageEnglish
Pages (from-to)32-39
Number of pages8
JournalCancer Letters
Volume289
Issue number1
DOIs
StatePublished - Mar 1 2010

Fingerprint

Immunologic Tests
alpha-Fetoproteins
Neoplasm Antigens
Autoantibodies
Hepatocellular Carcinoma
Chronic Hepatitis
Serum
Liver Cirrhosis
Antibodies
Antigens
Gene Library
Immunoassay
Recombinant Proteins
Neoplasms
Liver
Genes

Keywords

  • Alpha-fetoprotein (AFP)
  • Autoantibodies
  • Hepatocellular carcinoma
  • Immunodiagnostic markers
  • Tumor-associated antigens (TAAs)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. / Chen, Yao; Zhou, Yusen; Qiu, Suimin; Wang, Kaijuan; Liu, Siwei; Peng, Xuan Xian; Li, Junfeng; Tan, Eng M.; Zhang, Jian Ying.

In: Cancer Letters, Vol. 289, No. 1, 01.03.2010, p. 32-39.

Research output: Contribution to journalArticle

Chen, Yao ; Zhou, Yusen ; Qiu, Suimin ; Wang, Kaijuan ; Liu, Siwei ; Peng, Xuan Xian ; Li, Junfeng ; Tan, Eng M. ; Zhang, Jian Ying. / Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. In: Cancer Letters. 2010 ; Vol. 289, No. 1. pp. 32-39.
@article{45ca60bc70184bb2a429463714886525,
title = "Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma",
abstract = "The identification and characterization of tumor-associated antigens (TAAs) and their use in antigen mini-arrays for cancer immunodiagnosis has been of interest recently as an approach to cancer detection. In this study, autoantibodies in sera from a patient with HCC were used as probes to immunoscreen a HepG2 cDNA expression library for the identification of TAAs involved in malignant liver transformation. Recombinant proteins from two genes identified in this manner, Sui1 and RalA were expressed, purified and used as antigens in immunoassays to detect the presence of antibodies in sera from 77 patients with HCC, 30 with chronic hepatitis (CH), 30 with liver cirrhosis (LC) and 82 normal human sera (NHS). The prevalence of antibody to Sui1 and RalA in HCC were 11.7{\%} (9/77) and 19.5{\%} (15/77), respectively, which were significantly higher than prevalence in liver cirrhosis (3.3{\%} and 3.3{\%}), chronic hepatitis (0{\%} and 0{\%}) and normal human sera (0{\%} and 0{\%}). When Sui1 and RalA were added to a panel of eight other TAAs used in a previous study, the final cumulative prevalence of anti-TAA antibodies in HCC to the 10 TAA array was raised to 66.2{\%} (51/77). The specificity for HCC compared with LC, CH and NHS, was 66.7{\%}, 80.0{\%}, and 87.8{\%}, respectively. When anti-TAA was added to abnormal serum AFP as combined diagnostic markers, it raised the diagnostic sensitivity from 66.2{\%} to 88.7{\%}. AFP and anti-TAA were independent markers and the simultaneous use of these two markers significantly resulted in the increased sensitivity of HCC detection.",
keywords = "Alpha-fetoprotein (AFP), Autoantibodies, Hepatocellular carcinoma, Immunodiagnostic markers, Tumor-associated antigens (TAAs)",
author = "Yao Chen and Yusen Zhou and Suimin Qiu and Kaijuan Wang and Siwei Liu and Peng, {Xuan Xian} and Junfeng Li and Tan, {Eng M.} and Zhang, {Jian Ying}",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.canlet.2009.07.016",
language = "English",
volume = "289",
pages = "32--39",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma

AU - Chen, Yao

AU - Zhou, Yusen

AU - Qiu, Suimin

AU - Wang, Kaijuan

AU - Liu, Siwei

AU - Peng, Xuan Xian

AU - Li, Junfeng

AU - Tan, Eng M.

AU - Zhang, Jian Ying

PY - 2010/3/1

Y1 - 2010/3/1

N2 - The identification and characterization of tumor-associated antigens (TAAs) and their use in antigen mini-arrays for cancer immunodiagnosis has been of interest recently as an approach to cancer detection. In this study, autoantibodies in sera from a patient with HCC were used as probes to immunoscreen a HepG2 cDNA expression library for the identification of TAAs involved in malignant liver transformation. Recombinant proteins from two genes identified in this manner, Sui1 and RalA were expressed, purified and used as antigens in immunoassays to detect the presence of antibodies in sera from 77 patients with HCC, 30 with chronic hepatitis (CH), 30 with liver cirrhosis (LC) and 82 normal human sera (NHS). The prevalence of antibody to Sui1 and RalA in HCC were 11.7% (9/77) and 19.5% (15/77), respectively, which were significantly higher than prevalence in liver cirrhosis (3.3% and 3.3%), chronic hepatitis (0% and 0%) and normal human sera (0% and 0%). When Sui1 and RalA were added to a panel of eight other TAAs used in a previous study, the final cumulative prevalence of anti-TAA antibodies in HCC to the 10 TAA array was raised to 66.2% (51/77). The specificity for HCC compared with LC, CH and NHS, was 66.7%, 80.0%, and 87.8%, respectively. When anti-TAA was added to abnormal serum AFP as combined diagnostic markers, it raised the diagnostic sensitivity from 66.2% to 88.7%. AFP and anti-TAA were independent markers and the simultaneous use of these two markers significantly resulted in the increased sensitivity of HCC detection.

AB - The identification and characterization of tumor-associated antigens (TAAs) and their use in antigen mini-arrays for cancer immunodiagnosis has been of interest recently as an approach to cancer detection. In this study, autoantibodies in sera from a patient with HCC were used as probes to immunoscreen a HepG2 cDNA expression library for the identification of TAAs involved in malignant liver transformation. Recombinant proteins from two genes identified in this manner, Sui1 and RalA were expressed, purified and used as antigens in immunoassays to detect the presence of antibodies in sera from 77 patients with HCC, 30 with chronic hepatitis (CH), 30 with liver cirrhosis (LC) and 82 normal human sera (NHS). The prevalence of antibody to Sui1 and RalA in HCC were 11.7% (9/77) and 19.5% (15/77), respectively, which were significantly higher than prevalence in liver cirrhosis (3.3% and 3.3%), chronic hepatitis (0% and 0%) and normal human sera (0% and 0%). When Sui1 and RalA were added to a panel of eight other TAAs used in a previous study, the final cumulative prevalence of anti-TAA antibodies in HCC to the 10 TAA array was raised to 66.2% (51/77). The specificity for HCC compared with LC, CH and NHS, was 66.7%, 80.0%, and 87.8%, respectively. When anti-TAA was added to abnormal serum AFP as combined diagnostic markers, it raised the diagnostic sensitivity from 66.2% to 88.7%. AFP and anti-TAA were independent markers and the simultaneous use of these two markers significantly resulted in the increased sensitivity of HCC detection.

KW - Alpha-fetoprotein (AFP)

KW - Autoantibodies

KW - Hepatocellular carcinoma

KW - Immunodiagnostic markers

KW - Tumor-associated antigens (TAAs)

UR - http://www.scopus.com/inward/record.url?scp=75949088039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75949088039&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2009.07.016

DO - 10.1016/j.canlet.2009.07.016

M3 - Article

C2 - 19683863

AN - SCOPUS:75949088039

VL - 289

SP - 32

EP - 39

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -